Results 221 to 230 of about 75,755 (323)

Glycaemic control and variability with different commercially available hybrid closed loop systems in people with type 1 diabetes: A systematic review and meta‐analysis of randomized controlled trials

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue S1, Page 3-12, January 2026.
Abstract Aims To provide an updated analysis of the performance of different hybrid closed loop (HCL) systems in randomised controlled trials (RCTs) on subjects with type 1 diabetes. Materials and methods We conducted a systematic review with meta‐analysis. We searched four online databases and performed hand‐searching of conference proceedings to find
Sergio Di Molfetta   +8 more
wiley   +1 more source

Ventricular Fibrillation Caused by Hypokalaemia During a Diabetic Ketoacidosis

open access: bronze, 2019
Christopher M. Newman   +8 more
openalex   +1 more source

Weight loss in people with type 1 diabetes over 12 months: Real‐world data comparing tirzepatide, semaglutide and liraglutide

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 166-173, January 2026.
Abstract Aims This study aimed to compare the effects of tirzepatide, semaglutide, and liraglutide on body weight and metabolic risk markers over 12 months in people with body mass index ≥27 kg/m2 and type 1 diabetes (T1D). Methods This real‐world study included 250 people with obesity and T1D (female = 54.8%), treated with either tirzepatide (n = 35),
Ebaa Al Ozairi   +6 more
wiley   +1 more source

Efficacy and safety of once‐weekly basal insulin therapy in people with type 1 diabetes: A systematic review and meta‐analysis

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 210-220, January 2026.
Abstract Aims Once‐weekly basal insulins may offer similar or superior HbA1c reduction compared to once‐daily analogues in people with type 1 or type 2 diabetes. However, concerns about hypoglycaemia persist in individuals on multiple daily injections. This meta‐analysis (PROSPERO CRD42024606874) aimed to evaluate the efficacy and safety of once‐weekly
Ludovico Di Gioia   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy